BioNTech Archives - Page 18 of 20 - Medical Design Sourcing

Feds order 200M more vaccine doses from Pfizer, Moderna

[Photo by Daniel Schludi on Unsplash]

U.S. government agencies announced that they purchased a total of 200 million additional doses of COVID-19 vaccines from Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA).

The orders of 100 million doses from each of the only two FDA-authorized vaccines in the U.S. were made by the U.S. Health & Human Services Dept. (HHS) and the Defense Dept. (DoD). The U.S. has now purchased a total of 600 million doses, according to a news release, with the totals of the two-dose vaccines allowing for the vaccination of 300 million people.

Get the full story at our sister site, MassDevice.

Feds order 200M more vaccine doses from Pfizer, Moderna

[Photo by Daniel Schludi on Unsplash]U.S. government agencies announced that they purchased a total of 200 million additional doses of COVID-19 vaccines from Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA).

The orders of 100 million doses from each of the only two FDA-authorized vaccines in the U.S. were made by the U.S. Health & Human Services Dept. (HHS) and the Defense Dept. (DoD). The U.S. has now purchased a total of 600 million doses, according to a news release, with the totals of the two-dose vaccines allowing for the vaccination of 300 million people.

Each company is set to deliver 300 million doses in regular increments through the end of July 2021 while leveraging U.S.-based manufacturing capacity to produce in bulk.

“As the President directed, we are expanding our supply of COVID vaccines to protect people as quickly as possible,” Acting HHS Secretary Norris Cochran said in the release. “These purchases will allow us to accelerate our vaccination …

Report: Pfizer speeding up vaccine production

Pfizer (NYSE:PFE) is reportedly expecting to trim the time needed to produce COVID-19 vaccine batches to speed up production.

The company, which along with BioNTech (NSDQ:BNTX) developed one of two COVID-19 vaccines currently authorized in the U.S., is slated to cut the amount of time it takes to produce a batch of the vaccine from 110 days to an average of 60 days to increase efficiency, according to a USA Today report.

Get the full story at our sister site, MassDevice.

Report: Pfizer speeding up vaccine production

Pfizer (NYSE:PFE) is reportedly expecting to trim the time needed to produce COVID-19 vaccine batches to speed up production.

The company, which along with BioNTech (NSDQ:BNTX) developed one of two COVID-19 vaccines currently authorized in the U.S., is slated to cut the amount of time it takes to produce a batch of the vaccine from 110 days to an average of 60 days to increase efficiency, according to a USA Today report.

Get the full story at our sister site, MassDevice.

Report: Pfizer speeding up vaccine production

Pfizer (NYSE:PFE) is reportedly expecting to trim the time needed to produce COVID-19 vaccine batches to speed up production.

The company, which along with BioNTech (NSDQ:BNTX) developed one of two COVID-19 vaccines currently authorized in the U.S., is slated to cut the amount of time it takes to produce a batch of the vaccine from 110 days to an average of 60 days to increase efficiency, according to a USA Today report.

VP for operations for sterile injectables at Pfizer, Chaz Calitri, told USA Today that the company has already doubled output for the vaccine in the last month alone. The vaccine is made at three plants in the U.S., starting in Chesterfield, Mo., then going to Andover, Mass., before finishing in Kalamazoo, Mich.

According to the report, making the DNA to start the process of making the vaccine took 16 days at first but will soon take just nine or 10, all while the company maintains best manufacturing practices and complies with FDA regul…

Merck to supply lipids to boost Pfizer-BioNTech COVID-19 vaccine production

Merck (NYSE:MRK) announced that it’s expanding its partnership with BioNTech (NSDQ:BNTX) to supply lipids for the Pfizer (NYSE:PFE)/BioNTech COVID-19 vaccine.

The agreement will accelerate the supply of lipids and increase the amount of lipid delivery toward the end of 2021 so they can be used as part of the drug delivery system of mRNA therapies to the body, helping to make the vaccine effective, according to a news release.

Darmstadt, Germany-based Merck said it has worked to expand its already high lipid production capacity as it is currently combining with BioNTech to define exact requirements as they aim for a timely execution of the effort.

“What unites BioNTech and Merck KGaA, Darmstadt, Germany, is our strong belief in mRNA technology and our trustful collaboration in vaccine development,” Merck chairman & CEO Stefan Oschmann said in the release. “We are convinced that now is the time to pull together to supply as much vacci…

Which companies will likely produce the most COVID-19 vaccine in 2021?

Photo by Markus Spiske on Unsplash

Since the beginning of the pandemic, much of society has pinned its hopes on the availability of a vaccine. Now that several are available across the world, there is hope, said Dr. Anthony Fauci, chief medical advisor to President Joe Biden, in a recent JAMA interview. “There’s light at the end of the tunnel.”

One thing that will make the light at the end of the tunnel brighter as we head into the spring is the greater availability of vaccine doses. “The discordance between supply and demand will be diminished,” Fauci said.

The roster of companies producing vaccines is steadily increasing, making it possible to vaccinate a substantial portion of the world’s population this year. (Note: Most of the companies in this list have two-dose vaccines.)

Here’s a roundup of notable companies’ production targets for 2021:

AstraZeneca and Oxford University: Up to 3…

Study suggests Pfizer-BioNTech COVID-19 vaccine is effective against emerging variants

A Pfizer-BioNTech preprint published today suggests that their BNT162b2 vaccine will be effective against SARS-CoV2 variants from the U.K. and South Africa, leading to “small differences in viral neutralization” compared with earlier variants.

The U.K variant has been identified in 26 states in the U.S., while the South Africa variant has been found circulating in South Carolina.

The Pfizer and University of Texas Medical Branch scientists conducting the research concluded that modifying the BNT162b2 was unnecessary.

Get the full story from our sister site, Drug Discovery & Development.

Study suggests Pfizer-BioNTech COVID-19 vaccine is effective against emerging variants

A Pfizer-BioNTech preprint published today suggests that their BNT162b2 vaccine will be effective against SARS-CoV2 variants from the U.K. and South Africa, leading to “small differences in viral neutralization” compared with earlier variants.

The U.K variant has been identified in 26 states in the U.S., while the South Africa variant has been found circulating in South Carolina.

The Pfizer and University of Texas Medical Branch scientists conducting the research concluded that modifying the BNT162b2 was unnecessary.

The researchers, however, acknowledged that the study involving engineered viruses did “not include the full set of spike mutations found in the UK or SA variants” and that clinical data are required to better understand the impact of viral mutations on the vaccine.

The Pfizer findings are broadly similar to those from Moderna, whose experiments indicated that its mRNA-1273 vaccine is effective against emerging variants from the U.K.…

Sanofi to provide COVID-19 vaccine manufacturing for rival Pfizer

Sanofi (NYSE:SNY) announced today that it entered into an agreement to support the manufacturing and supply of the Pfizer/BioNTech COVID-19 vaccine.

Pfizer and BioNTech’s vaccine is one of two to receive FDA emergency use authorization in the U.S. and it also has clearance in Europe, having received both nods in December 2020.

The deal between Sanofi provides BioNTech access to its infrastructure and expertise to produce over 125 million doses of the COVID-19 vaccine in Europe. Initial supplies will originate from Sanofi’s production facilities in Frankfurt starting in the summer of 2021, according to a news release.

Get the full story at our sister site, Pharmaceutical Processing World.

Sanofi to provide COVID-19 vaccine manufacturing for rival Pfizer

Sanofi (NYSE:SNY) announced today that it entered into an agreement to support the manufacturing and supply of the Pfizer/BioNTech COVID-19 vaccine.

Pfizer and BioNTech’s vaccine is one of two to receive FDA emergency use authorization in the U.S. and it also has clearance in Europe, having received both nods in December 2020.

The deal between Sanofi provides BioNTech access to its infrastructure and expertise to produce over 125 million doses of the COVID-19 vaccine in Europe. Initial supplies will originate from Sanofi’s production facilities in Frankfurt starting in the summer of 2021, according to a news release.

“We are very conscious that the earlier vaccine doses are available, the more lives can potentially be saved. Today’s announcement is a pivotal step towards our industry’s collective goal of putting all the effort in to curb this pandemic,” Sanofi CEO Paul Hudson said in the release. “Although vaccination campaigns have started a…

White House could promise states additional COVID-19 vaccines doses next week

Image from René DeAnda on Unsplash

Federal shipments of COVID-19 vaccines could increase roughly 16% next week, potentially reducing some states’ shortfalls as they have broadened access to adults 65 and older.

The U.S. government plans to increase its weekly allocation to states from 8.6 million doses to approximately 10 million doses, according to The Washington Post.

Government authorities ship COVID-19 vaccine doses to 64 jurisdictions spread across the country and eight U.S. territories.

Moderna (NSDQ:MRNA) is likely to provide the supply boost.

Pfizer (NYSE:PFE) has decided to send the U.S. fewer doses of its vaccine jointly developed with BioNTech (NSDQ:BNTX) after the surprise discovery that its vials contained an extra dose. It negotiated with the U.S. government to count the extra sixth dose in its vials toward its prior commitment to provide 200 million doses.

Bot…